Industrial Partnerships / Licensing Opportunities / List of technologies available for licencing or transfer
Technology Transfer Office
LIST OF TECHNOLOGIES AVAILABLE FOR LICENSING - thematic filing
| MEDICAL APPLICATION | RESEARCH TOOLS | INDUSTRIAL APPLICATION |
Diagnostics
|
Animal models
Biological material / life sciences
Processes, techniques, screening
|
Agribusiness Environmental Hygiene Manufacturing Probiotics Vetenary medicine |
|
Diagnostics |
Therapeutics |
|||
| Immunotherapy | ||||
Allergy
| Allergy | ||
| D.I. n° | Inventor | Title |
|
01.77 |
Salah MECHERI |
A humanized mast cell system for the detection of functional human IgE : use for the detection of anaphylactogenic and anti-anaphylactogenic substances (biological material) |
|
98.44 |
Ulrich BLANK |
A humanized mast cell system fixing IgE |
Agribusiness
Agrochemicals
| Agrichemicals | ||
| D.I. n° | Inventor | Title |
|
00.07 |
Bernard DUJON |
Photorhabdus luminescens genome (TT01 strain) |
|
96.53 |
Robert LONGIN |
|
|
91.16 |
Armelle DELECLUSE |
|
Animal model
| Animal model | ||
| D.I. n° | Inventor | Title |
|
00.48 |
Jean-Pierre CHANGEUX |
Alpha6 nAChR subunit Knockout Mouse Model (ACNA6) |
|
98.01 |
Jean-Pierre CHANGEUX |
Alpha4 nAChR subunit Knockout Mouse Model (ACNA4) |
Biochemistry
| Biochemistry | ||
| D.I. n° | Inventor | Title |
| 05.52 | David PRANGISHVILI | The thermostable DNA polymerase from a virus of the hyperthemophilic archaeon Acidianus |
|
01.58 |
Liliane ASSAIRI |
Use of recombinant NAD kinase from bacillus subtilis and Neisseria meningitidis for the synthesis of NADP |
|
00.31/98.20 |
Philippe MARLIERE | In vivo production of proteins chemically diversified by incorporation of non-conventional amino acids: useful in vaccines, therapy, diagnosis and biocynthesis |
| 00.29 | Michel VERON | In vivo and in vitro synthesis of nucleoside triphosphate analogs using mutant nucleoside diphosphate kinase (NDPK) |
BioInformatics
| BioInformatics | ||
| D.I. n° | Inventor | Title |
|
04.31 |
Didier MAZEL |
Modulating mutational frequency to optimize protein evolution |
|
02.48 |
Alexis COLLETTE |
ISEApeaks :a strategy for global and statistical immune repertoire analysis. Use of the ISEApeaks software program as a tool in disease diagnosis and prognosis
|
|
02.03 |
Farid CHETOUANI |
DiffTool: bulding, visualizing and querying protein clusters
|
| 01.45 | Farid CHETOUANI | Find Target: a software tool for subtractive genome analysis |
| 01.43 | Lionel FRANGEUL | GMP-Tool-Box: a software package for bacterial genome sequencing projects from shotgun follow-up to annotation |
| 00.54 | Edouard YERAMIAN | Computational method for enhanced detection of genes and coding regions within long genomic sequences |
| 99.92 | Adrien SIX | A new software package to contribute to a comprehensive automation of immune repertoire analysis |
| 96.12 | Patrick GRIMONT |
Taxotron software for the automatic identification of bacteria
|
Biological Material
| Biological Material / Life sciences | ||
| D.I. n° | Inventor | Title |
| 05.52 | David PRANGISHVILI | The thermostable DNA polymerase from a virus of the hyperthemophilic archaeon Acidianus |
| 05.40 | Simon WAIN-HOBSON | Recovery of APOBEC3-edited human immunodeficiency virus G A hypermutants by differential DNA denaturation PCR |
| 05.39 | Simon WAIN-HOBSON | Recovery of APOBEC3-edited human immunodeficiency virus G A hypermutants by differential DNA denaturation PCR |
|
04.97/04.06/ |
Philippe BRULET |
Use of the CA2+ reporter GFP-aequorin for probing infection and physiology |
| 04.90-02.91 | Annette MARTIN | Chimeric GB virus B (GBV-B) : use in the development of treatments targeting Hepatitis C virus infection |
| 04.31 | Didier MAZEL | Modulating mutational frequency to optimize protein evolution |
| 04.17 | Armelle PHALIPON | Production and characterization of murine monoclonal antibodies specific for lipopolysaccharide and protecting against Shigella flexneri serotype 2a for (i) development of a diagnostic kit and (ii) characterization of known oligoside epitopes that could serve as the basis of a chemically-defined synthetic vaccine. |
| 04.14 | Frédéric TANGY | Infectious flavivirus pseudo-particles containing functional prM-E envelop proteins |
| 04.12 | Philippe DESPRES | Use of infectious retroviral pseudoparticles enveloped by flavivirus glycoproteins prM andt E for viral diagnostics and prophylaxis |
| 03.91 | Vincent DEUBEL | Novel golden Hamster model for henipavirus (Nipah-Hendra) infection |
| 03.64 | Lena EDELMAN | Anti-GPIV monoclonal antibodies |
| 03.27 | Pierre CHARNEAU | Non transformed cultured lines of embryonic mouse hepatic stem cells able to repopulate the mouse liver and ifferentiate into hepatocytes and bile ducts in vivo |
| 02.118 | Mireille MONTEBEYRIE | Monoclonal antibodies directed against the c-terminal end of the protein P2 ribosomal of Trypanosoma cruzi |
| 02.104 | Nancy GUILLEN | Entamoeba histolytica strain overexpressing the catalytic domain of protein kinase EhPAK |
| 02.100 | Faridabano NATO | Production of specific monoclonal antibodies against subunits A and B of cholera toxin (Biological Material) |
| 02.85 | Jean-Pierre CHANGEUX | CGRP in the treatment of nicotine withdrawal syndrome : transgenic mouse model |
| 01.13/02.57 | Alphonse GARCIA | Novel targeting peptides for intracellular delivery of compounds: research and therapeutic applications |
| 02.60 | Farida NATO | Rapid diagnosis of cholera based on immunochromatography |
| 02.59 | Anne BLANCHARD | Development and characterization of two monoclonal antibodies directed against the 15 C-terminal amino acids of aquaporin-2 and their evaluation using histologic sections of kidney from various species (human, rat, mouse) |
| 02.08 | Ara HOVANESSIAN | Hybridoma cell lines : 71/10 against the proteine kinase PKR ; 56/3 against the 2-5A synthetase 69 kDa ; 25/11 against the 2-5A synthetase 100 lDa |
| 01.77 | Salah MECHERI | A humanized mast cell system for the detection of functional human IgE : use for the detection of anaphylactogenic and anti-anaphylactogenic substances |
| 01.76 | Franck KUNST | Mise en évidence de composés ou de toxines produites par Photorhabdus luminescens au moyen de l’amibe Dictyostelium discoideum |
| 01.32 | Isabelle SAINT-GIRON | Restriction-modification system in Leptospira biflexa clone patoc 1 (biological material) |
| 01.20 | James DI SANTO | Novel strain of alymphoid mice for xenotransplantation |
| 00.59 | Claude LECLERC | B. pertussis adenylate cyclase-activating peptide receptor and its use in screening for immunologically/pharmacologically active molecules |
| 00.29 | Michel VERON | In vivo and in vitro synthesis of nucleoside triphosphate analogs using mutant nucleoside diphosphate kinase (NDPK) |
| 00.05 | Christophe D’ENFERT | cDNA library from Aspergillus nidulans for cloning of genes by functional complementation in S. cerevisiae yeast |
| 98.44 | Anna WEYER | A humanized mast cell system fixing human IgE: Use for screening of immunological and chemical reagents endowed with anaphylactogenic or anti-degranulating properties |
| 98.40 | Jean-Marc CAVAILLON | Hybridoma of anti-IL1 receptor antagonist |
| 98.17 | Fernando ARENZANA-SEISDEDOS | Monoclonal antibodies anti-SDF1 hybridomas |
Cancer
| Cancer | ||
| D.I. n° | Inventor | Title |
| 05.49 | Sylvie BAY | MUC6-Tn glycoconjugates mimicking cancer cells: applications to anti-tumor immunotherapy |
| 04.107 | Matthew ALBERT | Prostaglandin E2 induces indoleamine 2.3 deoxygenase expression and works in synergy with TNF-SF and TLR ligands to trigger its activity |
|
03.88 |
Fabrice AGOU |
Functional characterization of minimal oligomerization domain of NEMO |
|
03.83 |
Marie-Annick BUENDIA |
Transgenics mice representing animal models of liver carcigenesis |
|
03.68 |
Hervé BOURHY |
Identification of a peptide motif of lyssavirus matrix protein involved in the induction of apoptosis : therapeutic applications
|
| 03.53 | Claude LECLERC | Synthetic glycopeptide vaccines : applications in anti-tumoral immunotherapy |
| 03.32 | Yu-Chun LONE | Generation of mice that are doubly transgenic for HLA-A21 HLA-DR1 and doubly knocked-out for H-2 class 1 et Il (b2mO r Ilabo rKO) for the preclinical development of new vaccines |
| 03.13 | Jean-Michel THIBERGE | Simplified method for molecular typing of Helicobacter pylori (H. pylori) isolates |
| 01.13/02.57 | Alphonse GARCIA | Novel targeting peptides for intracellular delivery of compounds: research and therapeutic applications |
| 02.76/02.84 | Alphonse GARCIA | Protein phosphatase 2A (PP2A)-targeting peptides designed for intracellular transfer and anti-apoptotic activity |
| 02.70 | Eric PRINGAULT | In vitro model system for the study of prevention of dysplasias and adenocarcinomas arising from the intestinal metaplasias of Barrett’s syndrome |
| 02.57 | Alphonse GARCIA | Intracellular transfer of protein phosphatase 2A (PP2A)-targeting peptides: novel strategy for the inhibition of tumoral and infectious processes |
| 01.62 | Alphonse GARCIA | Protein Phosphatase 2A-chemokine receptor CXCR4, CC-5 and CD28 binding sites: novel targets for inhibition of HIV infection and tumor development |
| 00.03 | Philippe DESPRES | Apoptotic sequence |
| 96.61/99.62 | Claude LECLERC | MAG: A new family of optimized synthetic glycopeptidic vaccines with high therapeutic activity |
| 96.42/95.33 | Claude LECLERC | Recombinant parvovirus-like particles for inducing cytotoxic T-cell response: use in antiviral and antitumoral drugs or vaccines |
Diagnostics - Biomarckers
Diagnostics - Environment / Industry
Diagnostics - Infections diseases
| Diagnostics - Infections diseases | ||
| D.I. n° | Inventor | Title |
| 09.17 | Vincent ENOUF | Molecular test for the detection of Influenza A virus subtype H1N1. |
| 08.68 | Carmen BUCHRIESER | Molecular typing and diagnostic of Legionella pneumophila and Legionella longbeachae: Identification of marker genes and specific probes for simultaneous identification of the species and the serogroup in the environment and the patient |
| 08.31 | Hugues BEDOUELLE | Simplified serological assays of infections by flaviviruses and other viruses, using hybrids between a viral protein domain and alkaline phosphatase |
| 05.35 | Suzanne CHANTEAU | New rapid diagnostic tests for Neisseria meningitidis serogroups A, W135, C, and Y. |
| 04.32 | Ralf ALTMEYER | Optimized genes for increased SARS Co V Spike protein expression |
| 04.14 | Frédéric TANGY | Infectious flavivirus pseudo-particles containing functional prM-E envelop proteins |
| 04.12 | Philippe DESPRES | Use of infectious retroviral pseudoparticles enveloped by flavivirus glycoproteins prM andt E for viral diagnostics and prophylaxis |
| 03.101 | Philippe GLASER | Complete sequence of Listeria monocytogenes strain CLIP80459. Use in genomic typing of Listeria monocytogenes and risk assessment |
| 03.78 | Patrick GRIMONT | Molecular approach for capsular typing of Klebsiella |
| 03.75 | Claude LECLERC | Recombinant CyaA toxins : diagnostic and immunomonitoring applications |
| 03.33 | Dana PHILPOTT | Sensing of a unique muropeptide gram-negative bacterial peptidoglycan (PGN) by Nod1: drug screening, diagnostic and therapeutic applications |
| 03.13 | Jean-Michel THIBERGE | Simplified method for molecular typing of Helicobacter pylori (H. pylori) isolates |
| 03.04 | Sylvie BAY | Phosphorylcholine-glycoconjugates and their synthesis : diagnostic and therapeutic applications |
| 02.122 | Pascale COSSART | Use of Listeria bile salt hydrolase to develop detection, diagnostic and therapeutic tools |
| 02.118 | Mireille MONTEBEYRIE | Monoclonal antibodies directed against the c-terminal end of the protein P2 ribosomal of Trypanosoma cruzi |
| 02.60 | Farida NATO | Rapid diagnosis of cholera based on immunochromatography |
| 02.56 | Jean-Marc GHIGO | Identification of an external membrane protein family involved in interbacterial interactions during biofilm formation and conjugative transfer of genes: applications in the development of bacteria-BioR biofilm control procedures |
| 02.30 | Michèle BOULOY | Recombinant antigen for the serological diagnosis of Puumala hantavirus infection |
| 02.10 | Stewart COLE | Specifically deleted tubercular bacillus sequences for the rapid identification of M. tuberculosis and other members of the M. tuberculosis complex |
| 01.63 | Antoine DANCHIN | Partial sequencing and annotation of Penicllium marneffei genome |
| 01.47 | Brigitte GICQUEL | Probes for the identification of M. tuberculosis strains with accrued virulence and capable of housing or leading to the acquisition of antibiotic resistance genes |
| 01.41 | Christophe d’ENFERT | Specific probes of Candida albicans yeast genome |
| 00.75 | Suzanne CHANTEAU | Simple and rapid diagnosis of human plague |
| 00.44 | Bernard DUJON | Microsatellite typing kit for the identification of yeast strains: food testing and human diagnostic applications |
| 00.43 | Bernard DUJON | Novel nucleotide sequences of Saccharomyces cerevisiae and their use in the detection of hemiascomycetous yeasts |
| 00.25 | Gilles MARCHAL | Immunogenic glycopeptides derived from Mycobacterium tuberculosis: diagnostic and vaccine applications |
| 98.51 | Stewart COLE | Deleted sequences in M. bovis BCG/M. bovis or M. tuberculosis genomes: diagnostic and vaccine applications |
| 98.31 | Brigitte GICQUEL | New sequences of M. tuberculosis and the identification of associated genes |
| 97.44 | Stewart COLE | Genomic analysis method for the detection and identification of mycobacteria |
| 96.07 | Patrick GRIMONT | Probes for 16 S RNA : detection of E. Coli or Shigella |
| 91.13 | Gilles MARCHAL | Mycobacterium Proteins and their applications (naxi test) |
Diagnostics - Methods
| Diagnostics - Methods | ||
| D.I. n° | Inventor | Title |
|
05.40 |
Simon WAIN-HOBSON |
|
|
05.39 |
Simon WAIN-HOBSON |
Recovery of APOBEC3-edited human immunodeficiency virus G A hypermutants by differential DNA denaturation PCR |
| 02.48 | Alexis COLLETTE | ISEApeaks :a strategy for global and statistical immune repertoire analysis. Use of the ISEApeaks software program as a tool in disease diagnosis and prognosis |
| 01.22 | Marie-Louise GOUGEON | Novel cytofluorometric method for quantitation and characterization of cell-mediated cytotoxic activity |
| 99.68/69 | Hugues BEDOUELLE | Novel antibody-based fluorescence biosensor using no additional reagents |
| 97.49 | Philippe METEZEAU | Chromosomic laser microdissection: process for cytogenetics abnormalities detection |
Diagnostics - Non Infections diseases
| Diagnostics - Non Infections Diseases | ||
| D.I. n° | Inventor | Title |
| 08.90 | Marie-Annick BUENDIA | Molecular markers of hepatocellular carcinoma: uses for prognosis and as potential therapeutic targets |
| 08.71 | Catherine ROUGEOT | Opiorphin, as a biomarker. Development and validation of a competitive ELISA for Opiorphin to establish its quantitative profile of secretion and distribution in human |
|
02.82 |
François ROUGEON |
HC antibodies and their derivatives obtained through the immunization of camelids against human beta -amyloid peptide: use in the diagnosis and treament of Alzheimer’s disease |
|
00.11 |
Alain ISRAËL |
Detection of mutations in Nemo gene: use in diagnosis of familial incontinentia pigmenti |
| 00.10 | Huseyin FIRAT | Hybridomas producing anti-HLA-H antibodies for the diagnosis of human hemachromatosis |
| 98.30 | Jean-Luc GUESDON | Molecular diagnostic for prelingual deafness |
| 97.32 | Christine PETIT | Polynucleotides for detecting a frequent mutation responsible for prelingual non-syndromic deafness in the connexin 26 gene |
Environment
| Environment | ||
| D.I. n° | Inventor | Title |
|
01.01 |
Pierre BEGUIN | Sequence of Photorhabdus luminescens genome (TT01 strain) |
Gene Therapy
| Gene Therapy | ||
| D.I. n° | Inventor | Title |
| 01.13/02.57 | Alphonse GARCIA | Novel targeting peptides for intracellular delivery of compounds: research and therapeutic applications |
| 96.69 | Pierre CHARNEAU | Central DNA Flap Sequence for new Lentiviral Vectors |
| 96.02 | Denise PAULIN | Promotor of the SM22 gene and its applications for cardiovascular gene therapy |
| 94.32 | Denise PAULIN | Desmine Promotor and its applications for gene therapy |
Genomics
| Genomics | ||
| D.I. n° | Inventor | Title |
|
04.31 |
Didier MAZEL | Modulating mutational frequency to optimize protein evolution |
| 01.63 | Antoine DANCHIN | Partial sequencing and annotation of Penicllium marneffei genome |
| 98.30 | Jean-Luc GUESDON | Molecular diagnostic for prelingual deafness |
| 97.44 | Stewart COLE | Genomic analysis method for the detection and identification of mycobacteria |
HIV
| HIV | ||
| D.I. n° | Inventor | Title |
| 05.40 | Simon WAIN-HOBSON | Recovery of APOBEC3-edited human immunodeficiency virus A G hypermutants by differential DNA denaturation PCR |
| 05.39 | Simon WAIN-HOBSON | Recovery of APOBEC3-edited human immunodeficiency virus A G hypermutants by differential DNA denaturation PCR |
|
02.111 |
Ara HOVANESSIAN | A universal B-cell epitope vaccine against HIV infection |
| 01.68 | Fernando ARENZANA-SEISDEDOS | Human langerin is the principal receptor expressed by Langerhans cells permitting HIV envelope glycoprotein binding |
| 01.62 | Alphonse GARCIA | Protein Phosphatase 2A-chemokine receptor CXCR4, CC-5 and CD28 binding sites: novel targets for inhibition of HIV infection and tumor development |
| 01.55 | Pierre LANGLADE-DEMOYEN | News HIV1 epitopics peptides |
| 01.20 | James DI SANTO | Une nouvelle souche de souris alymphoïde pour la xenotransplantation |
| 99.86 | Olivier SCHWARTZ | A screening method to identify new HIV inhibitors |
| 99.38 | Ralf ALTMEYER | A new method for rapid screening of drugs inhibiting HIV entry |
Hygiene
| Hygiene | ||
| D.I. n° | Inventor | Title |
|
03.35 |
Jean-Marc GHIGO | Culture method for the study of Biofilms in continuous flux. Use in the study of bacteria-surface interactions |
| 96.53 | Robert LONGIN | MultiMicroFermentors |
Immunotherapy
| Immunotherapy | ||
| D.I. n° | Inventor | Title |
|
02.46 |
Pierre DRUILHE | Anti-MSP3 recombinant antibodies |
| 02.30 | Michèle BOULOY | Recombinant antigen for the serological diagnosis of Puumala hantavirus infection |
| 01.49 | Salah MECHERI | Determination of vaccine protective potential using mastocyte-activating salivary antigens from mosquitos |
| 96.61/99.62 | Claude LECLERC | MAG: A new family of optimized synthetic glycopeptidic vaccines with high therapeutic activity |
Inflammation
| Inflammation | ||
| D.I. n° | Inventor | Title |
|
06.16 |
Pedro ALZARI | A novel neurotrophin species linked to inflammation, chronic pain and neuropathology as a target for drug design and immunotherapy |
| 04.111 | Stephen E. GIRARDIN | Screening for Nod-modifying drugs to treat Crohn’s disease |
| 03.88 | Fabrice AGOU | Functional characterization of minimal oligomerization domain of NEMO |
| 03.33 | Dana PHILPOTT | Sensing of a unique muropeptide gram-negative bacterial peptidoglycan (PGN) by Nod1: drug screening, diagnostic and therapeutic applications |
| 02.86 | Daniel SCOTT-ALGARA | Novel therapy for the treatment of atherosclerosis and inflammatory processes induced by pathogenic agents |
Neurobiology
| Neurobiology | ||
| D.I. n° | Inventor | Title |
|
06.16 |
Pedro ALZARI | A novel neurotrophin species linked to inflammation, chronic pain and neuropathology as a target for drug design and immunotherapy |
| 04.97/04.06/ 98.03 |
Philippe BRULET | Use of the CA2+ reporter GFP-aequorin for probing infection and physiology |
| 03.42 | Benoit ROBERT | Msx1 and Msx2 are required for the integrity and functionality of the dorsal roof plate of the neural tube, maintaining a non neuronal identity of the roof plate cells. Use in screening and identification of genes involved in differentiation, proliferation and maintainance of glial lineage |
| 02.103 | Thomas BOURGERON | Mutation of neuroligin HNL3 gene in autism and the identification of the sequence of MNL4, the gene ortholog of HNL4X in mouse |
| 02.97 | Daniel GONZALES-DUNIA | 2’Fluoro-2’-deoxycytidine inhibits Borna Disease Virus Replication and Spread |
| 02.85 | Jean-Pierre CHANGEUX | CGRP in the treatment of nicotine withdrawal syndrome : transgenic mouse model |
| 02.82 | François ROUGEON | HC antibodies and their derivatives obtained through the immunization of camelids against human beta -amyloid peptide: use in the diagnosis and treament of Alzheimer’s disease |
| 02.58 | Jean-Michel HEARD | Treatment of central nervous system lesions associated with lysosomal storage disease by intracerebral injection of AAV vectors |
| 01.80 | Jean-Pierre CHANGEUX | Utilisation de souris mutantes pour la sous unité nicotinique beta 2 pour trier des molécules qui modulent les symptômes de sevrage à la nicotine |
| 01.71 | Jean-Claude MAZIE | Mouse monoclonal antibody C11 58,2 directed against Tetanus neurotoxin-Insensitive Vesicle Associated Membrane Protein (TI-VAMP or SybL1p) |
| 01.69 | Mannich BUENDIA | Beta-catenin and FHL2 interactions in Alzheimer disease: therapeutic applications |
| 01.61 | Thomas BOURGERON | A frameshift mutation of HNL4, a primate specific X-linked neuroligin, is associated with autistic disorder and Asperger |
| 00.49 | Jean-Pierre CHANGEUX | Transgenic mice with mutations of the beta2 subunit of the neuronal nicotinic acetylcholine receptor (nAChR) |
| 00.48/98.01 | Jean-Pierre CHANGEUX | Mutant mice deleted for different nicotinic acetylcholine receptor subunits |
| 00.21 | Hoang-Oanh NGHIEM | Purification of histidine kinase proteins and their use in phosphorylation of proteins involved in allergy |
Processes
| Processes | ||
| D.I. n° | Inventor | Title |
|
04.32 |
Ralf ALTMEYER |
Optimized genes for increased SARS Co V Spike protein expression |
|
04.31 |
Didier MAZEL | Modulating mutational frequency to optimize protein evolution |
| 03.76 | Armand BERNEMAN | Screening procedure for potential inhibitors of proline racemase |
| 02.56 | Jean-Marc GHIGO | Identification of an external membrane protein family involved in interbacterial interactions during biofilm formation and conjugative transfer of genes: applications in the development of bacteria-BioR biofilm control procedures |
| 97.49 | Philippe METEZEAU | Chromosomic laser microdissection: process for cytogenetics abnormalities detection |
| 96.53 | Robert LONGIN | MultiMicroFermentors |
Proteomics
| Proteomics | ||
| D.I. n° | Inventor | Title |
|
04.31 |
Didier MAZEL |
Modulating mutational frequency to optimize protein evolution |
|
00.31/98.20 |
Philippe MARLIERE | In vivo production of proteins chemically diversified by incorporation of non-conventional amino acids: useful in vaccines, therapy, diagnosis and biocynthesis |
| 99.72 | Yves JACOB | Constrained peptides libraries for use in a combinatorial approach to selecting molecules of pharmacological interest |
| 96.53 | Robert LONGIN | MultiMicroFermentors |
Research tools
Therapeutics anopheles
| Therapeutics anophele | ||
| D.I. n° | Inventeur | Titre |
| 05.35 | Suzanne CHANTEAU | New rapid diagnostic tests for Neisseria meningitidis serogroups A, W135, C, and Y. |
Therapeutics bacterial
| Therapeutics bacterial | ||
| D.I. n° | Inventor | Title |
| 04.27 | Anthony PUGSLEY | A novel antimicrobial target specific to Gram-negative bacteria |
| 03.33 | Dana PHILPOTT | Sensing of a unique muropeptide gram-negative bacterial peptidoglycan (PGN) by Nod1: drug screening, diagnostic and therapeutic applications |
| 03.13 | Jean-Michel THIBERGE | Simplified method for molecular typing of Helicobacter pylori (H. pylori) isolates |
| 02.62 | Elisabeth CARNIEL |
Identification of genes specifically expressed in Y pestis and Y pseudotuberculosis |
| 02.28 | Stewart COLE | Novel antigens for the diagnosis, prevention and treatment of mycobacteriosis |
| 01.82 | Antoine DANCHIN |
Identification of pharmacologic targets during methylthioribose (MTR) recycling and events involved in post-traduction modification of lysine residues by carbamylation |
| 01.63 | Antoine DANCHIN | Partial sequencing and annotation of Penicllium marneffei genome |
| 01.53 | Maurice HOFNUNG | "Big Blue" transgenic mice as animal models of chronic Helicobacter pylori infection and their use in the evaluation of the effects of therapeutic compositions on gastric mutagenesis |
| 00.26 | Agnès LABIGNE | Genomic random library of H. pylori |
| 00.01 | Franck KUNST | Sequence of Photorhabdus luminescens genome (TT01 strain) |
| 98.08 | Agnès LABIGNE | UreI protein: a novel target for Helicobacter pylori eradication therapy |
Therapeutics biofilm
Therapeutics cancer
| Therapeutics Cancer | ||
| D.I. n° | Inventeur | Titre |
|
04.02 |
François LEMONNIER | Evaluation of the protective capacity of cellular immune response completely restricted to human HLA alleles induced in vivo in the absence of murine response competition in mice doubly transgenic for HLA-A2/HLA-DR1 and double knockout for H-2 class 1&II (b2m°/°/lab°/°KO) against viral challenge. Vaccine and immunology applications for preclinical development of new vaccines. |
| 03.83 | Marie-Annick BUENDIA | Transgenics mice representing animal models of liver carcigenesis |
| 03.68 | Hervé BOURHY | Identification of a peptide motif of lyssavirus matrix protein involved in the induction of apoptosis : therapeutic applications |
| 02.76 | Alphonse GARCIA |
Protein phosphatase 2A (PP2A)-targeting peptides designed for intracellular transfer and anti-apoptotic activity |
| 02.57 | Alphonse GARCIA | Intracellular transfer of protein phosphatase 2A (PP2A)-targeting peptides: novel strategy for the inhibition of tumoral and infectious processes |
| 01.62 | Alphonse GARCIA | Protein Phosphatase 2A-chemokine receptor CXCR4, CC-5 and CD28 binding sites: novel targets for inhibition of HIV infection and tumor development |
| 96.61/99.62 | Claude LECLERC | MAG: A new family of optimized synthetic glycopeptidic vaccines with high therapeutic activity |
| 96.42/95.33 | Claude LECLERC | Recombinant parvovirus-like particles for inducing cytotoxic T-cell response: use in antiviral and antitumoral drugs or vaccines |
Therapeutics cardiovascular, hematology, thrombosis
| Therapeutics cardiovascular, hematology, thrombosis | ||
| D.I. n° | Inventor | Title |
|
03.12 |
Jean-François POULIN | DNA construct for assessing thymic function activity and therapeutical uses thereof |
| 02.86 | Daniel SCOTT-ALGARA | Novel therapy for the treatment of atherosclerosis and inflammatory processes induced by pathogenic agents |
| 01.13/02.57 | Alphonse GARCIA | Novel targeting peptides for intracellular delivery of compounds: research and therapeutic applications |
| 96.02 | Denise PAULIN | Promotor of the SM22 gene and its applications for gene therapy |
Therapeutics central nervous system
| Therapeutics central nervous system | ||
| D.I. n° | Inventor | Title |
| 02.82 | François ROUGEON | HC antibodies and their derivatives obtained through the immunization of camelids against human beta -amyloid peptide: use in the diagnosis and treament of Alzheimer’s disease |
| 02.44 | Pierre LAFAYE | Monoclonal antibodies directed against calreticulin: diagnostic and intracellular targeting applications |
| 01.69 | Mannich BUENDIA | Beta-catenin and FHL2 interactions in Alzheimer disease: therapeutic applications |
| 01.61 | Thomas BOURGERON | A frameshift mutation of HNL4, a primate specific X-linked neuroligin, is associated with autistic disorder and Asperger |
| 99.36/85 | François ROUGEON | Bioactive peptides derived from submandibular rat 1 protein (SMR1) and its derivatives: therapeutic and diagnostic applications |
Therapeutics compounds library
| Thérapeutics Compouds library | ||
| D.I. n° | Inventor | Title |
|
99.72 |
Yves JACOB | Constrained peptides libraries for use in a combinatorial approach to selecting molecules of pharmacological interest |
Therapeutics fungi
Therapeutics hepatitis
| Therapeutics Hepatitis | ||
| D.I. n° | Inventor | Title |
| 06.53 | Matthew L. ALBERT | sIP-10, CD26 activity and responsiveness to therapy in chronic HCV patients |
| 04.90-02.91 | Annette MARTIN |
Chimeric GB virus B (GBV-B) : use in the development of treatments targeting Hepatitis C virus infection |
| 04.64 | Agata BUDKOWSKA | Cell entry of hepatitis C virus via human scavenger receptor hSR-BI. Screening for candidate therapeutic molecules capable of inhibiting HCV/SR-BI |
| 04.29 | Yves RIVIERES | T-cell immunogenicity of protein core+ 1 in chronic carriers of hepatitis C virus. Therapeutic and/or vaccine applications |
| 03.07 | Ralf ALTMEYER | Interaction of HCV glycoproteins with dendritic cell and liver endothelial call lectins DC-SIGN and L-SIGN |
| 02.83 | Catherine TRANSY |
Molecular tools for the selection of human primary hepatocytes infected with hepatitis C virus (HCV): use in the development of novel antiviral molecules and in the study of molecular interactions between HCV and host cell |
Therapeutics VIH
| Therapeutics VIH | ||
| D.I. n° | Inventor | Title |
| 04.47 | Frédéric TANGY | Anti-HIV-1 activity of dermaseptin S4, a broad spectrum antimicrobial: potential use as a local microbicide for the prevention of mucosal HIV transmission during sexual intercourse |
| 01.68 | Fernando ARENZANA-SEISDEDOS | Human langerin is the principal receptor expressed by Langerhans cells permitting HIV envelope glycoprotein binding |
| 99.86 | Olivier SCHWARTZ | A screening method to identify new HIV inhibitors |
| 99.38 | Ralf ALTMEYER | A new method for rapid screening of drugs inhibiting HIV entry |
Therapeutics malaria
| Therapeutics Malaria | ||
| D.I. n° | Inventor | Title |
| 05.18 | Jean-Claude BARALE | Methods for detecting virulent Plasmodium for evaluating Plasmodium virulence, and for screening new drugs employing the 3’UTR of Plasmodium SUB2 and Plasmodium SUB2 serine protease |
| 00.19 | Jüng GYSIN | Novel proteins involved in cytoadhesion of Plasmodium falciparum-infected erythrocytes: diagnostic and vaccine applications |
Therapeutics parasitology
| Therapeutics parasitology | ||
| D.I. n° | Inventor | Title |
| 03.76 | Armand BERNEMAN | Screening procedure for potential inhibitors of proline racemase |
| 02.127 | Paola MINOPRIO | Crystallographic structure of Trypanosoma cruzi proline racemase |
| 02.118 | Mireille MONTEBEYRIE | Monoclonal antibodies directed against the c-terminal end of the protein P2 ribosomal of Trypanosoma cruzi |
| 02.04 | Michel VERON | Novel Plasmodium falciparum antigen DG 571 for the induction of protection against challenge infection with Plasmodium sporozoite |
| 00.80 | Hechmi LOUZIR | Vaccine against leishmaniasis using virulence antigen P55 gene |
| 00.19 | Jüng GYSIN | Novel proteins involved in cytoadhesion of Plasmodium falciparum-infected erythrocytes: diagnostic and vaccine applications |
| 00.13 | Isabelle TARDIEUX | Therapeutic use of specific domains of toxofilin, a novel actin-binding protein from Toxoplasma gondii |
Therapeutics pain
| Therapeutics pain | ||
| D.I. n° | Inventor | Title |
| 08.19 | Catherine ROUGEOT | New opiorphin (QRFSR) Peptide deritatives as potent dual inhibitor of enkephalin-degrading ectopeptidases |
| 08.06 | Catherine ROUGEOT | Therapeutic applications of opiorphin, as -analgesic- anti-depressant psychostimulant molecule without the majour side-effects of morphine |
| 08.05 | Catherine ROUGEOT | Palmitoyl - QRFSR - CONHZ EFFECT ON hNEP and hAP-N |
| 08.02 | Catherine ROUGEOT | FRET - Based enzyme in vitro models - Validation on hNEP & hAP-N activity - Effect of Orpiophin derivatives |
|
06.16 |
Pedro ALZARI | A novel neurotrophin species linked to inflammation, chronic pain and neuropathology as a target for drug design and immunotherapy |
| 99.36/85 | François ROUGEON | Bioactive peptides derived from submandibular rat 1 protein (SMR1) and its derivatives: therapeutic and diagnostic applications. |
Therapeutics tuberculosis
| Therapeutics tuberculosis | ||
| D.I. n° | Inventor | Title |
| 04.109 | Stewart COLE | Pyranodibenzofuran derivatives with antifungal and bacterial activity |
| 02.28 | Stewart COLE | Novel antigens for the diagnosis, prevention and treatment of mycobacteriosis |
| 02.26 | Brigitte GICQUEL | Recombinant Mycobacterium bovis BCG (rBCG) strains expressing chicken ovalbumin (ova) gene included within replicating or integrating vectors |
| 02.22 | Olivier SCHWARTZ | Role of DC-SIGN/DC209 in Mycobacterium tuberculosis attachment and entry into human dendritic cells and role of lipoarabinomannan (LAM) as a DC-SIGN ligand |
| 01.24 | Hélène MUNIER-LEHMANN | M. tuberculosis thymidylate kinase (TMPK) inhibitors: use in the development of new antitubercular drugs |
Therapeutics vaccines
| Therapeutics vaccines | ||
| D.I. n° | Inventor | Title |
| 03.04 | Sylvie BAY | Phosphorylcholine-glycoconjugates and their synthesis : diagnostic and therapeutic applications |
| 00.69 | Alice DAUTRY-VARSAT | Methods for prevention or treatment of Chlamydia infection |
| 00.59 | Claude LECLERC | B. pertussis adenylate cyclase-activating peptide receptor and its use in screening for immunologically/pharmacologically active molecules |
Therapeutics viral
Vaccines
| Vaccines | ||
| D.I. n° | Inventor | Title |
| 09.20 | Rajeekumar TAWAR | X-ray structure of a (Respiratory Syncytial Virus) Nucleoprotein-RNA template-like assembly |
| 09.08 | Laurence MULARD | Rationally designed liposome-based diepitope constructs as glycoimunogens and their use in vaccine compositions : application to Shigella flexneri serotype 2a |
| 05.49 | Sylvie BAY | MUC6-Tn glycoconjugates mimicking cancer cells: applications to anti-tumor immunotherapy |
| 05.38 | Ralf ALTMEYER | Purified trimeric S protein as vaccine against Severe Acute Respiratory Syndrome virus infections |
| 05.37 | Marie-Louise MICHEL | Identification of T-cell epitopes derived from HBSP protein of HBV |
| 05.12 | Shirley LONGACRE | Recombinant Plasmodium Falciparum merozoite surface proteins 4 and 5 their use |
| 04.29 | Yves RIVIERES | T-cell immunogenicity of protein core+ 1 in chronic carriers of hepatitis C virus. Therapeutic and/or vaccine applications |
| 04.12 | Philippe DESPRES | Use of infectious retroviral pseudoparticles enveloped by flavivirus glycoproteins prM andt E for viral diagnostics and prophylaxis |
| 04.02 | François LEMONNIER | Evaluation of the protective capacity of cellular immune response completely restricted to human HLA alleles induced in vivo in the absence of murine response competition in mice doubly transgenic for HLA-A2/HLA-DR1 and double knockout for H-2 class 1&II (b2m°/°/lab°/°KO) against viral challenge. Vaccine and immunology applications for preclinical development of new vaccines. |
| 03.53 | Claude LECLERC | Synthetic glycopeptide vaccines : applications in anti-tumoral immunotherapy |
| 03.44 | Pierre DRUILHE | Gene family cluster encoding proteins targeted by antibodies effective at killing Plasmodium falciparum erythrocytic stages |
| 03.43 | Claude LECLERC | Identification of the Bordetella pertussis adenylate cyclase domain that interacts with its receptor the integrin (CD11b/CD18) |
| 03.19 | Steward COLE | Use of Mycobacterium tuberculosis RD1 in vaccine applications |
| 02.95 | Brigitte GICQUEL | BCG strain with an inactivating mutation of the ureC gene |
| 02.91 | Annette MARTIN | An infectious chimeric GB virus B containing the core domain III of the HepatitisC virus (HCV) ires that is infectious and causes hepatitis in tamarins : a new animal model for HCV studies |
| 02.83 | Catherine TRANSY | Molecular tools for the selection of human primary hepatocytes infected with hepatitis C virus (HCV): use in the development of novel antiviral molecules and in the study of molecular interactions between HCV and host cell |
| 02.24 | Philippe DESPRES | Yellow fever molecular determinant M-36 and its role in the attenuation of various anti-amaril vaccine strains through modulation of proapototic activity of hepatotropic flavirirus |
| 02.21 | Philippe DESPRES | Analysis of the immune capacities of recombinant measles viruses expressing Env and NS1 from yellow fever virus |
| 02.20 | Frédéric TANGY | Recombinant measles viruses expressing the native envelope glycoprotein of HIV1 clade B or envelopes with deleted variable loops induce humoral and cellular immune responses |
| 02.19 | Frédéric TANGY | Production of an infectious cDNA of the Schwarz strain of measles vaccine |
| 02.06 | Pierre DRUILHE | Novel Plasmodium falciparum antigen DG 571 for the induction of protection against challenge infection with Plasmodium sporozoite |
| 01.87 | Armand BERNEMAN | Potential adjuvant effect of T. cruzi proline racemase (TcPA45) |
| 01.65 | Claude LECLERC | Use of viral pseudo-particles (PPV-PLPS) for targeting and activation of dendritic cells and their adjuvant effect |
| 01.63 | Antoine DANCHIN | Partial sequencing and annotation of Penicllium marneffei genome |
| 01.55 | Pierre LANGLADE-DEMOYEN | News HIV1 epitopics peptides |
| 01.54 | Claude LECLERC | B. pertussis adenylatecyclase receptor: use in screening for immunologically/pharmacologically active molecules |
| 01.40 | Frédéric TANGY | Generation of an Infectious cDNA corresponding to the antigenome of the Schwarz Vaccine Strain of Measles Virus |
| 01.31 | Pierre DRUILHE | Identification of two novel Plasmodium falciparum antigens involved in host response to the pre-erythrocyte stages of the parasite |
| 01.24 | Hélène MUNIER-LEHMANN | M. tuberculosis thymidylate kinase (TMPK) inhibitors: use in the development of new antitubercular drugs |
| 01.23 | Jean-Michel FOURNIER | Novel vaccine composition inducing protective antibodies against cholera |
| 01.13 | Pierre DRUILHE | Phosphatase A2 protein binding sites for HIV-1 Vpr protein and parasite Theileria protein kinase CK2-alpha: two new targets for viral, parasitic or tumoral indications |
| 00.80 | Hechmi LOUZIR | Vaccine against leishmaniasis using virulence antigen P55 gene |
| 00.31/98.20 | Philippe MARLIERE | In vivo production of proteins chemically diversified by incorporation of non-conventional amino acids: useful in vaccines, therapy, diagnosis and biocynthesis |
| 00.25 | Gilles MARCHAL | Immunogenic glycopeptides derived from Mycobacterium tuberculosis: diagnostic and vaccine applications |
| 99.75 | Michèle BOULOY | Attenuated Rift Valley Fever Virus: human and veterinary vaccine applications |
| 99.44 | Pierre DRUILHE | Mucosal immunization using lipid-tailed peptides without adjuvant |
| 98.51 | Stewart COLE | Deleted sequences in M. bovis BCG/M. bovis or M. tuberculosis genomes: diagnostic and vaccine applications |
| 98.31 | Brigitte GICQUEL | New sequences of M. tuberculosis and the identification of associated genes |
| 96.61/99.62 | Claude LECLERC | MAG: A new family of optimized synthetic glycopeptidic vaccines with high therapeutic activity |
| 96.42/95.33 | Claude LECLERC | Recombinant parvovirus-like particles for inducing cytotoxic T-cell response: use in antiviral and antitumoral drugs or vaccines |
| 96.26 | Armelle PHALIPON | Novel immunogenic polypeptides for the induction of protective immune response against pathogenic microorganisms and method for their production |
| 91.13 | Gilles MARCHAL | Mycobacterium Proteins and their applications (naxi test) |
Veterinary medecine
| Veterinary medecine | ||
| D.I. n° | Inventor | Title |
|
04.14 |
Frédéric TANGY | Infectious flavivirus pseudo-particles containing functional prM-E envelop proteins |
|
04.12 |
Philippe DESPRES | Use of infectious retroviral pseudoparticles enveloped by flavivirus glycoproteins prM andt E for viral diagnostics and prophylaxis |
| 03.19 | Steward COLE | Use of Mycobacterium tuberculosis RD1 in vaccine applications |
| 02.97 | Daniel GONZALES-DUNIA | 2’Fluoro-2’-deoxycytidine inhibits Borna Disease Virus Replication and Spread |
| 02.28 | Stewart COLE | Improved vaccines for the prevention of tuberculosis infection in animals |
| 01.13 | Pierre DRUILHE | Phosphatase A2 protein binding sites for HIV-1 Vpr protein and parasite Theileria protein kinase CK2-alpha: two new targets for viral, parasitic or tumoral indications |
| 00.20 | Michel Y. POPOFF | Un nouveau traitement préventif de la salmonellose chez l’animal |
| 00.04 | Nicole GUISO-MACLOUF | Antigenic variants of pertactin in Bordetella: diagnostic and immunogenic applications in veterinary field |
| 99.75 | Michèle BOULOY | Attenuated Rift Valley Fever Virus: human and veterinary vaccine applications |